The Regeneron Surge
This month’s cover feature is another in our series highlighting industry’s “stealth players”– companies with the pipelines and management potential to join the ranks of big Pharma over the next decade. New York-based Regeneron has time and technology squarely in its corner, with a leading franchise in antibody therapeutics, in-depth scientific expertise in the burgeoning, compound-rich field of cell biology; a seasoned management team, and the global roots that stem from longstanding product partnerships with heavyweights like Bayer and Sanofi.

Medicines Adherence: Raise that ROI!
Pharm Exec surveys the current changing landscape of patient adherence programs, as companies address the impact of US health reform, the transformative technologies of mobile apps and gamification, and increasing commitments of employers to make taking your medicine almost a condition for the retention of individual health benefit coverage. Winning corporate programs selected by a panel of expert judges at the Center for Business Intelligence [CBI] 12th annual Patient Adherence and Support Summit will be profiled, based on direct input from the sponsors on key success factors that will generate markedly higher rates of ROI around a comprehensive adherence agenda.

The Russia Playbook
Forget Napoleon – there is more than mud on the road to Moscow. Despite declining demographics, a confusing and discriminatory regulatory environment, and persistent corruption, Russia remains a market of substantial long-term promise for big Pharma. In this comprehensive survey of local business practices, Pharm Exec identifies ways to cope with a changing stakeholder environment; manage the impact of major ongoing reforms in drug registration, pricing, quality manufacturing and distribution; and build reputation through airtight legal compliance – because the trust that comes from being seen as local partner of choice is the long-term currency for success in Russia.